Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Novartis (NOVN.S)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (CHF)	Price Target (CHF)	Rating
2023-04-28	85.21	80.41	Neutral
2023-05-18	85.14	92.565	Neutral
2023-07-19	83.17	88.825	Neutral
2023-10-04	87.60	90.00	Neutral
2024-01-15	92.00	104.00	Buy
2024-04-24	89.12	108.00	Buy
2024-07-19	94.20	111.00	Buy
2025-02-13	97.78	104.00	Neutral
2025-07-22	92.15	95.00	Neutral
2025-11-04	101.48	102.00	Neutral
2026-01-16	115.60	116.00	Neutral

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.